Physician profile
Robert T Torrano
NPI 1306854708
$57,140.80
in general payments reported to CMS, 2019-2025
32 companies · $1,398 in 2025
The $1,398 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $860 · 2020: $5,627 · 2021: $8,567 · 2022: $11K · 2023: $29K · 2024: $1,407 · 2025: $1,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $4,709 · Travel and Lodging: $759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,000.00 |
| Food and Beverage | $4,709.44 |
| Travel and Lodging | $759.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $51,831.09 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,066.84 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Csl Behring | $361.87 | 2020-2025 | Hizentra, Haegarda, Andembry |
| Octapharma USA, INC. | $336.43 | 2020-2025 | Cutaquig |
| Genzyme Corporation | $235.51 | 2019-2025 | |
| Pfizer INC. | $222.23 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.95 | 2020-2022 | |
| Alk-Abello, INC | $189.20 | 2019-2023 | Odactra, Grastek |
| Grifols USA, LLC | $163.36 | 2020-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $148.45 | 2020-2025 | Cuvitru, Takhzyro |
| Amgen INC. | $135.76 | 2023-2025 | Tezspire, Actimmune |
| Genentech USA, INC. | $134.95 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $134.53 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $124.84 | 2019-2025 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $107.50 | 2025 | Neffy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $92.11 | 2019-2025 | Ruconest |
| Optinose US, INC. | $81.84 | 2019-2024 | |
| Blueprint Medicines Corporation | $75.41 | 2024 | Ayvakit |
| Teva Pharmaceuticals USA, INC. | $67.56 | 2019-2022 | |
| Kaleo, INC. | $52.01 | 2019-2021 | |
| Lilly USA, LLC | $49.62 | 2024-2025 | Ebglyss |
| Horizon Therapeutics Plc | $49.60 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $42.37 | 2019-2023 | |
| Ionis Pharmaceuticals, INC. | $41.57 | 2025 | Dawnzera |
| Covis Pharma Gmbh | $39.83 | 2019 | |
| Biocryst US Sales Co., LLC | $30.03 | 2025 | Orladeyo |
| Hikma Pharmaceuticals USA | $24.38 | 2023 | Ryaltris |
| Kowa Pharmaceuticals America, INC. | $23.34 | 2025 | Zoryve |
| Hospira, INC. | $22.80 | 2023 | |
| Philips North America LLC | $21.97 | 2019 | |
| Mylan Specialty L.P. | $16.80 | 2019 | |
| Uswm, LLC | $12.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Torrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.